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Abstract
Background: CD105 was postulated as a renal cell carcinoma (RCC) stem cell marker, and CD133 as a putative RCC
progenitor. Hypoxia, a natural microenvironment that prevails in tumors, was also incorporated into the study, especially
in terms of the promotion of hypothetical stem-like cell properties.
Methods: Within this study, we verify the existence of CD105+ and CD133+ populations in selected papillary
subtype RCC (pRCC) cell lines. Both populations were analyzed for correlation with stem-like cell properties,
such as stemness gene expression, and sphere and colony formation. For the preliminary analysis, several RCC
cell lines were chosen (786-O, SMKT-R2, Caki-2, 796-P, ACHN, RCC6) and the control was human kidney cancer
stem cells (HKCSC) and renal cells of embryonic origin (ASE-5063). Four cell lines were chosen for further investigation:
Caki-2 (one of the highest numbers of CD105+ cells; primary origin), ACHN (a low number of CD105+ cells; metastatic
origin), HKCSC (putative positive control), and ASE-5063 (additional control).
Results: In 769-P and RCC6, we could not detect a CD105+ population. Hypoxia variously affects pRCC cell growth,
and mainly diminishes the stem-like properties of cells. Furthermore, we could not observe the correlation of CD105
and/or CD133 expression with the enhancement of stem-like properties.
Conclusions: Based on this analysis, CD105/CD133 cannot be validated as cancer stem cell markers of pRCC cell lines.
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Background
Renal cell carcinoma (RCC) is the seventh most common
tumor and is associated with high mortality [1]. Several
subtypes of RCC have been defined: clear cell RCC
(ccRCC; 70% incidence), papillary RCC (pRCC; 10% inci-
dence), chromophobe RCC (ChRCC; 5% incidence), and
rare types of RCC where the frequency is less than 1% of
each [2]. The estimated statistics for 2016 in the United
States predict about 62,700 new cases of kidney cancer
(63.2% in men) and 14,240 deaths (64.9% in men) from
the disease. The renal cancer 5-year survival rate is stage
dependent and ranges from 8 to 81% for TNM stage IV
and I, respectively [3]. Up to 30% of RCC patients have
metastatic spread at the initial presentation [4]. Moreover,
even after a nephrectomy, RCC recurs within the first
5 years in 40% of patients with an initially localized
disease. As recently shown, disease recurrence and metas-
tasis development may be mediated by cancer stem cells
(CSCs) [5], which are a rare subpopulation of tumor cells
suspected of playing a critical role in cancer progression.
Despite the low numbers found, unique properties allow
CSCs to mediate tumor development, growth, metastatic
spread, and treatment resistance [6]. CSCs are charac-
terized by self-renewal and multilineage differentiation
potential. These cells may generate all cell subpopula-
tions of the tumor and are characterized by the overex-
pression of Oct4, Sox2, and Nanog transcription factors
(TFs) [7, 8], increased activity of ABC transporters and
aldehyde dehydrogenase (ALDH)1, and the presenta-
tion of specific surface markers [9]. Moreover, CSCs are
characterized by functional assays, including clonogenic
assay, growth in non-adhesive spheroids, or the generation
of in vivo serially transplantable carcinomas. Identification
and isolation of CSCs from other tumor cells is still a
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source of debate [10], and it appears that all the above
mentioned tests need to be conducted to properly
recognize CSCs [11, 12].
In the case of RCC, putative CSCs markers were pro-
posed, including CD105 [13], CXCR-4 [14], DNAJB8
[15], and ALDH [16, 17]. Moreover, some RCC CSC
populations were isolated with functional approaches
[18–24].
One of the well-known CSC inducers is hypoxia. Due to
an uncontrolled proliferation of cancer cells and parallel in-
efficient tumor vascularization, a microenvironment within
tumors is characterized by low oxygen tension (<1% O2)
[25]. Tumor hypoxia drives the production and release of
angiogenic factors [26] by cancer cells, and it may lead to
changes in cancer cell metabolism. Multiple mechanisms
induced by hypoxia, including microRNA expression [27]
and the activation of HIF1-3 proteins [28], may promote
CSC phenotypes; therefore, an oxygen microenvironment
should be taken into consideration in CSC research.
In this study, we aimed to identify CD105+ cells in
established RCC cell lines and to verify if those cells
possess characteristics of CSCs as Bussolati et al. [13]
showed that CD105+ cells isolated from primary RCC
tumors have CSC characteristics. Using multiple methods,
we evaluate if a similar population exists in established
RCC cell lines, and verify the influence of oxygen in CSC
induction, which could serve as a valuable tool to investi-
gate CSC functions in RCC pathology.
Methods
Cell lines
Human primary RCC cell lines, HKCSC, 786-O, SMKT-
R2, Caki-2, 769-P, and metastatic ACHN and RCC6,
were used. RCC6 cells were a kind gift from Prof. Salem
Chouaib (INSERM, Institut Gustave Roussy, Villejuif,
France). SMKT-R2 cells were gifted by Prof. T. Tsukamoto
and Dr. S. Tochizawa (School of Medicine, Sapporo
Medical University, Sapporo, Japan). Also, 786-O, Caki-2,
ACHN, and 769-P were bought from ATCC (Manassas,
VA, USA), and human healthy kidney epithelial cell line
ASE-5063 was bought from Applied StemCell Inc.
(Milpitas, CA, USA). HKCSCs (human kidney CSCs;
36117-44-T75 of papillary origin) were obtained from
Celprogen (Torrance, CA, USA). All cell lines were
analyzed until the tenth passage of cells, which were
originally stocked in our laboratory.
Cell culture
Cells were cultured in 75 cm2 cell culture flasks (Orange
Scientific) in RPMI-1640/GlutaMax medium (Gibco,
Paisley, Scotland, UK), apart from HKCSCs, which were
maintained in Human Kidney Cancer Stem Cell Complete
Growth Medium (Celprogen, Torrance, CA, USA). RPMI-
1640 was supplemented with 10% FBS (Hyclone, Utah,
USA/Gibco, Paisley, Scotland, UK) and treated with
antibiotics (Penicillin-Streptomycin solution, Sigma, St.
Louis, MO, USA) to a final concentration of 100 IU/mL
penicillin and 100 μg/mL streptomycin. After thawing, the
cells were passaged at least once before being used in
experiments. After reaching 80% of confluence, the cells
were harvested by trypsinization (0.25% trypsin, 0.03%
EDTA solution; Invitrogen, Carlsbad, CA, USA), counted
in an automated cell counter MOXI Z (Orflo, Ketchum,
ID, USA), and used in experiments described below. Cells
were seeded at an appropriate concentration in different
tissue culture vessels (Table 1) and kept in an normoxic
incubator for 24 h to allow cells to attach and then be
used in assays. In the hypoxia experiments, after an initial
24 h incubation in normoxia, the cells were moved into a
hypoxic incubator, cultured for an appropriate amount of
time, and used in cell assays. Cells cultured in normoxic
conditions served as a control. Cells were cultured
according to standard mammalian tissue culture
protocols and sterile techniques in normoxia (5%
CO2; 37 °C) and hypoxia (1% O2; 5% CO2; 37 °C)
incubators.
Cell proliferation measurement
Cells were cultured in 96-well plates as described above.
The measurement of cell viability using alamarBlue®
(Invitrogen, Carlsbad, CA, USA) was performed every
day for a total of 6 days according to the manufacturer’s
protocol. The medium was exchanged after 3 days of
culture. The absorbance of alamarBlue® was measured
using Multiskan™ GO Microplate Spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA) at
570 nm and 600 nm. The absorbance obtained from
readings was then calculated to a percentage reduction
of alamarBlue®.
Cell cycle analysis
Cells were cultured in 6-well plates as described above.
After 72 h incubation, cells with approximately 80%
confluence were collected with trypsin. The cells were
washed in PBS and fixed in ice-cold 70% ethanol for
30 min at −20 °C. The fixed cells were washed three
times and suspended in PBS containing 50 μg/mL of
RNase A for 30 min, then incubated with 50 μg/mL pro-
pidium iodide (PI; Cayman Chemical, Ann Arbor, MI,
USA) for 30 min in the dark. Subsequently, the samples
Table 1 Number of cells seeded in culture vessels
Cell line T75 6 well plate 96 well plate
Caki-2 500 000 60 000 1000
ACHN 950 000 120 000 2000
HKCSCs 250 000 30 000 500
ASE 1 200 000 150 000 3000
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were acquired in a FACSCalibur (Becton Dickinson, San
Diego, CA, USA) system and PI incorporation was esti-
mated using CellQuest Pro software (Olympus, Tokyo,
Japan). For each measurement, at least 25,000 cells were
acquired. An analysis of the cell cycle was performed
using the Watson modelling algorithm from the FlowJo
software (Ashland, OR, USA).
Gene expression analysis
Cells were cultured in 75 cm2 cell culture flasks as de-
scribed above. After 72 h incubation, cells with approxi-
mately 80% confluence were collected by trypsinization.
Total RNA Mini Plus (A&A Biotechnology, Gdynia,
Poland) was used for total RNA isolation according to
the manufacturer’s protocol. Eventually, RNA was eluted
from the column with RNase-free water. The concentra-
tion and purity of RNA were determined by measuring
the absorption at 230 nm, 260 nm, and 280 nm in a
Multiskan™ GO Microplate Spectrophotometer. A
TranScriba Kit (A&A Biotechnology, Gdynia, Poland)
was used to generate full-length first strand cDNA from
total RNA templates. An oligo-(dT) primer was used
for the transcription of RNA by a Moloney murine
leukemia virus reverse transcriptase. Five μg of total
RNA in 20 μL of reaction mix was used for reverse
transcription. Single strand complementary DNA (cDNA)
generated in rtPCR was used as a template for amplification
by sqPCR. Real-time PCR was performed with gene-
specific primers and probes (listed in Table 2) and TaqMan®
Universal Master Mix II, no UNG (Applied Biosystems,
Foster City, CA, USA). Reactions were performed in 20 uL
volume, with 2 μL of cDNA template, according to the
manufacturer’s instructions, on the StepOne real-time PCR
system (Applied Biosystems, Foster City, CA, USA) in 48-
well plates. Data were calculated with the 2(−Delta C(T))
method, with normalization to mean expression of pepti-
dylprolyl isomerase A (PPIA) as a housekeeping gene.
Fluorescence-activated cell sorter
Cells were cultured in 6-well plates as described above.
After 72 h culture, cells with approximately 80% confluence
were collected with Accutase (BDSciences, San Diego, CA,
USA) and analyzed for CD105 and CD133 marker expres-
sions. Cells were stained with (i) CD105-PE (BD Pharmin-
gen, San Diego, CA, USA, clone 266) plus CD133/1-APC
(Miltenyi Biotec, Bergisch Gladbach, Germany, clone
AC133); or (ii) CD105-FITC (Biolegend, San Diego, CA,
USA, clone 43A3) plus CD133/2-APC (Miltenyi Biotec,
Bergisch Gladbach, Germany, clone 293C3) according to
the manufacturers’ protocols with the appropriate isotype
controls. Subsequently, the samples were acquired in a
FACSCalibur system. For each measurement, at least
10,000 cells were acquired. Data were analyzed by Flowing
Software (Turku Centre for Biotechnology, Turku, Finland).
Colony formation assay
The ability to create colonies was measured with the use
of the semi-soft agar method [29]. Cells after passage
were collected as described above, and 2,000 cells were
seeded into a 96-well plate according to the Stem Cell
Colony Formation Assay (Cell Biolabs, San Diego, CA,
USA) protocol. Cells were cultured for 21 days, and
every 7 days photos of the colonies were taken using an
inverted light microscope (Olympus CKX41, Tokyo,
Japan) with CellSens software (Olympus, Tokyo, Japan).
Additionally, colonies formed after 2 weeks were used
for quantitative analysis; agar was liquefied by Lysis So-
lution and repetitive pipetting. Half of the obtained col-
onies were mixed 1:1 with the RPMI medium containing
20% alamarBlue® in a 96-well plate and after 3 h incuba-
tion they were analyzed as described in Section 2.4.
Sphere formation assay
After passage, cells were collected as described above and
washed twice with PBS to remove any remaining medium
with serum. Cells were counted and seeded at 5,000 cells/
mL on non-adherent 24-well plates (TC plate, suspension,
F, Sarstetd, Numbrecht, Germany) in 500 mL per well of
DMEM (with GlutaMax, Gibco, Paisley, Scotland, UK)
and supplemented with antibiotics (100 IU/mL penicillin
and 100 μg/mL streptomycin, Sigma, St. Louis, MO,
USA), b27 (1×; Gibco, Paisley, Scotland, UK), epidermal
growth factor (20 ng/mL; Invitrogen, Carlsbad, CA, USA),
and basic fibroblast growth factor (25 ng/mL; Invitrogen,
Carlsbad, CA, USA). Cells were cultured for 5 days and
photos of the spheroids were taken using an inverted light
microscope (Olympus CKX41, Tokyo, Japan). For quanti-
tative analysis, formed spheroids were counted from five
representative microscope fields by two independent
experimenters using CellSens software (Olympus, Tokyo,
Japan).
Wound healing assay
Cell migration was determined using a wound healing
assay. After passage, cells were collected as described
above and seeded in 6-well plates, in an appropriate
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medium, in densities forming a confluent monolayer.
After 24 h incubation, a linear wound was created using
a 1 mL pipette tip. Cells were washed with PBS to re-
move detached cells and were cultured in an appropriate
medium for 24 h in hypoxic and normoxic incubators.
The wound spaces were imaged under an inverted
microscope (at 40× magnification; Olympus) at 0 h and
24 h at the same field. Wound healing was analyzed
using WimScratch software, according to the following
formula: wound healing area (%) = [cell-free area (0 h) −
cell-free area (24 h)]/cell-free area (0 h) × 100. Each
scratch was performed in triplicate.
Hanging drop assay
After passage, the cells were collected as described
above and seeded at 500 cells per 15 μL drop of ap-
propriate medium on the inner side of a 100 mm
Petri dish lid. The lid was turned upside down and
placed on top of the dish filled with 10 mL of PBS.
Cells were observed daily for 10 days to detect the
creation of aggregates. Photos were taken using an
inverted light microscope (Olympus CKX41, Tokyo,
Japan). For quantitative analysis, areas of formed
aggregates were counted from three representative
microscope fields (drops) by two independent experi-
menters using CellSens software (Olympus, Tokyo,
Japan).
Immunocytochemistry
Cells were cultured in 75 cm2 cell culture flasks as de-
scribed above. After 72 h incubation, cells with approxi-
mately 80% confluence were collected with Accutase, and
suspended in PBS. Then cells were centrifuged and re-
suspended in 4% PFA for 10 min at room temperature.
PFA was removed by centrifugation, and cells were placed
in ddH2O onto ICC SuperFrost microscope slides (Thermo
Scientific, Hennigsdorf, Germany, 10143560WCUT) and
allowed to dry. The staining was performed in a Flex
Autostainer instrument (Dako, Glostrup, Denmark) and
with the use of EnVisionFlex kits (Dako, Glostrup,
Denmark). Antigen retrieval was performed with 5 min
proteinase incubation for CD105 or 1 h incubation in a tar-
get retrieval solution (pH= 6) for CD133. After the block-
ade of endogenous peroxidase activity, the slides were
incubated for 1 h with primary antibodies: mouse anti-
human CD105 (Dako, Glostrup, Denmark, M3527, clone
SN6h), or rabbit anti-human CD133 (Biorbyt, Cambridge,
UK, polyclonal, orb18124). After washing, the slides were
incubated with appropriate secondary antibodies labelled
with HRP. For CD105 staining, HRP activity was amplified
with the FLEX+ Mouse Linker. Visualization was per-
formed with Flex DAB+ chromogen. Slides were counter-
stained with hematoxylin (Dako, Glostrup, Denmark,
CS700), coverslipped with Pertex (HistoLab, Gothenburg,
Sweden, 00840) and observed in a light microscope (Olym-
pus CKX41, Tokyo, Japan).
Statistical analysis
Data are presented as the mean values ± SD or ratios
(hypoxia/normoxia). Each experiment was performed
at least three times with three technical replicates.
The differences between the groups studied were
considered significant when the P-value was less
than 0.05 in the Student’s t-Test calculated in MS
Excel (Microsoft), and were designated with an as-
terisk on graphs (P < 0.1 is designated with a double
asterisk).
Results
CD105+ and CD133+ subpopulations analysis in RCC cell
lines
Among an evaluated panel of established RCC cell lines,
including primary tumor derived and metastasis derived
(Table 3), the CD105+ subpopulation was confirmed
with FACS in majority of cell lines with Caki-2 and
SMKT-R2 cell lines presenting the highest number of
Table 3 Summary of cell line origin and CD105/CD133 occurrence
Cell line RCC subtype
(reference)
Stage CD105 CD133
FACS Real-time PCR FACS Real-time PCR
786-O clear cell [42–44] primary + NA NA NA
769-P clear cell [42, 43] primary ND NA NA NA
SMKT-R2 Mixed [45] primary +++ NA NA NA
RCC6 Papillary [46] primary ND NA NA NA
Caki-2 Papillary [31, 32, 47] primary +++ +++ + +++
ACHN Papillary [32, 48] metastatic + + + ND
ASE Normala embryonal ++ + +++ ++
HKCSC Papillarya primary +/ND ND +/ND ND
+++ - strong expression, ++ - mean expression, + - weak expression
ND not detected (no expression), NA not applicable; not determined
aSupplier Certificate of Analysis
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positive cells, which was more than 25%. In the 786-O
and ACHN lines, less than 5% of cells were CD105+,
while no positive cells were detected in 769-P and RCC6
(Fig. 1). As a positive control, HKCSCs obtained from a
primary papillary RCC tumor [30] were used, but the
CD105+ subpopulation was hardly detectable in this cell
line. At the same time, a substantial number of CD105+
cells were detected in an ASE cell line, which were
normal renal cells of embryonic origin (Fig. 2a and b).
For further analyses, HKCSCs, ASE, Caki-2 (high
CD105 expression), and ACHN (low expression) cell
lines were selected. Caki-2 and ACHN cell lines were re-
cently evaluated as derivatives of papillary RCC [31–34];
therefore, we have focused on these cell lines because
CSCs in pRCC have not been described until today.
A high number of CD105+ cells in Caki-2 were con-
firmed in ICC staining—one-third of the cells were posi-
tive for this marker (Fig. 2d)—and CD105 expression
was detected on the mRNA level (Fig. 2c). In contrast,
CD105+ cells in ACHN could not be detected in the
ICC method (Fig. 2d), but low expression of this gene
was found by the qPCR approach (Fig. 2c).
The CD133 receptor as the RCC progenitor cell’s puta-
tive marker [35–37] was also evaluated. The Caki-2 cell
line had a slightly larger CD133+ subpopulation than the
ACHN cell line (Fig. 3a), but mRNA was detectable only
in the former (Fig. 3b). The number of CD133+ cells in
both cell lines was very low as established by FACS and
ICC (data not shown) consistently with previously pub-
lished data for RCC cell lines [38]. Interestingly, CD133
expression was significant in the ASE cell line as most cells
were positive for this marker. This was also consistent with
data reported elsewhere for both fetal [39] and adult renal
cells [40].
CD105 populations and stem-like properties
To test if the CD105 expression correlated with the
stem-like properties of pRCC cell lines, the expression of
oct4 and sox2 genes—markers of embryonic, adult, and
CSC—was evaluated, but only oct4 expression was sig-
nificantly higher in CD105-high cells (Caki-2). The ex-
pression of oct4 and sox2 was also detected in ASE cells,
but not in HKCSCs (Fig. 4).
Sphere and colony formation assays [41] were used for
the functional identification of stem-like cell-rich cultures.
Only ACHN and HKCSCs were able to form colonies in
semi-soft agar (Fig. 5a). A quantitative AlamarBlue assay
showed a significantly increased amount of viable HKCSC
colonies compared with ACHN. After 2 weeks of culture,
ACHN cells created round, sphere-like colonies that
increased in volume until the third week. HKCSCs formed
mulberry-like colonies with rough edges as soon as 7 days
after seeding; however, the colonies seemed not to grow
significantly during further culture.
In sphere-promoting culture conditions (DMEM, FGF,
EGF, and B27 medium), only ACHN and Caki-2 cells
were viable (Fig. 5b). ACHN cells created large aggre-
gates that fused over time, while Caki-2 cells formed
smaller, irregular sphere-like structures. ACHN spheres
were significantly bigger than Caki-2 spheres, although
there were no significant differences in sphere number
between them.
Cell–cell cohesion properties were screened in a
hanging drop assay, and Caki-2 and ASE cells formed
the aggregates, while HKSCSs created a compact
structure with firm edges (Fig. 6). Throughout the
study, an ACHN line grew in culture as loose cells.
Less compacted structures of Caki-2, ACHN, and ASE
aggregates were significantly bigger in size than the
compacted HKCSC.
Hypoxia differentially affected pRCC cell growth
Cell line characteristics also were described in hypoxic
conditions with the assumption that low O2 would pro-
mote stemness features. Both pRCC cell lines Caki-2
and ACHN overexpressed hif1, in comparison to tested
normal renal ASE cells, but the level of the hif2 gene
was lower than in the ASE cells (Fig. 7a). In response to
hypoxia, ACHN cells up-regulated hif2 expression and
reduced growth by G2/M arrest (Fig. 7c). In the case of
Caki-2 cells, the reaction was the opposite; the expres-
sion of both hif1 and hif2 was slightly decreased but the
cells exhibited a mild increase in the rate of proliferation
in hypoxia, as did normal renal cells (Fig. 7b).
In response to hypoxia, the ACHN cell line in-
creased the expression of stemness TFs: oct4 and
Fig. 1 Percentage of CD105 positive cells within RCC cell lines. RCC
cell lines were cultured in normoxic conditions, and after the third
day, cells were analyzed by flow cytometry for the CD105 surface
marker. The graph shows a relative amount of CD105+ cells in
relation to isotype control (threshold). The highest number of CD105+
(more than 25%) was identified in the primary tumor derived Caki-2
and SMKT-R2 cell lines. Similar CD105+ levels were observed in another
primary tumor derived 786-O and metastatic ACHN, while in 769-P
(primary) and RCC6 (metastatic) no positive cells were detected
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sox2 (Fig. 8a). The CD133+ subpopulation enumer-
ation was slightly increased by the low level of O2
(Fig. 8b), but the percentage of CD105+ cells slightly
reduced with the increase in CD105 mRNA levels.
Likewise, the Caki-2 cell line reaction to hypoxia
was similar: stem-related TFs and CD133 expression
(the latter at the protein level only) increased, but
CD105 decreased (Fig. 8). Conversely, in the ASE
cell line, both CD133 and CD105 subpopulations
reduced in hypoxia. However, oct4 and sox2 expres-
sion increased in low O2. This shows the differential
effect of oxygen levels on pRCC cell line features.
Despite the induction of the expression of some stem-
related genes by hypoxia, stem phenotype is mostly not
expressed more intensively in low O2 in tested pRCC
cells (Fig. 9). ACHN cells showed reduced colony- and
sphere-forming abilities in hypoxia along with reduced
cell growth (alamarBlue® assay; Fig. 7b). At the same
Fig. 2 CD105 expression on protein and mRNA level. For further analysis, Caki-2 (high expression), ACHN (low expression), HKCSC (control), and
ASE (control) were used. a Representative dot plots of CD105 and CD133 expression in tested cell lines. b Percentage of CD105+ cells in tested
cell lines measured by flow cytometry. Within control cell lines, only normal renal cells of embryonic origin (ASE) had a CD105+ population, while
in the commercially available renal cancer stem cell line (HKCSC), this population was hardly detected. c Relative expression of CD105 gene was
measured by real-time PCR in relation to the PPIA housekeeping gene. CD105 expression was significantly upregulated in Caki-2 and downregulated in
ACHN; a similar observation was made in the FACS analysis. d ICC staining was done to confirm Caki-2 and ACHN flow cytometry results. Around one-third
of Caki-2 cells were positive for the CD105 marker with significant expression. However, in ACHN CD105+ cells were not detected with this method
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time, HKCSCs, which grow equally well in hypoxia and
normoxia in 2D, showed a different morphology of col-
onies created in semi-soft agar. The hypoxia colonies
were smaller and less compacted than the normoxic
ones. Only Caki-2 cells developed more spheres in low
O2 compared to spheres developed in normoxia.
The wound healing assay showed the most reduced
cell migration ability of all the tested cell lines in hypoxia
(Fig. 10a). However, the hypoxia inhibition of cell migra-
tion was statistically significant only in ACHN and
HKCSC. Photos were taken immediately after scratch
and after 24 h hypoxic or normoxic incubation (Fig. 10b).
This indicated that the migration capacity of the ana-
lyzed cell lines was inhibited by low O2.
Comparison of the cell line origin and the CD105/CD133
presence or absence
Results obtained from CD105/CD133 FACS and real-
time PCR analysis were listed (Table 3) in reference to
the appropriate cell line origin.
Discussion
Previous studies have reported that CD105+ cells may
represent a tumor-initiating stem cell population in RCC
[13, 42]. However, due to the low abundance of this
subpopulation in total tumor samples, the number of
studies on CD105+ cells in RCC is limited and they are
mostly based on primary cultures and nephrectomy
specimens [36]. We aimed to set a feasible laboratory
Fig. 3 CD133 expression on protein and mRNA levels. The CD133 receptor was evaluated within CAKI-2, ACHN, HKCSC, and ASE cell lines. a
Percentage of CD133+ cells measured by flow cytometry. Caki-2 had a significantly higher number of CD133+ cells than ACHN. An extremely
high number of CD133+ population was identified in ASE; in contrast, in HKCSC, the population was not detected. b The relative expression
of cd133 measured by real-time PCR normalized to the PPIA housekeeping gene. Gene expression showed a different profile in comparison to
flow cytometry; the relative expression of cd133 was higher in Caki-2 than ASE. The gene expression was not detectable in ACHN and HKCSC
Fig. 4 Expression of “stemness genes”. Relative expression of oct4 and sox2 stem-related genes was measured by real-time PCR in relation to the
PPIA housekeeping gene. Statistically significant differences were obtained between Caki-2 and ACHN for the oct4 gene. Interestingly, in HKCSC,
neither gene was detected. In contrast, the oct4 relative expression in ASE (normal renal cells of embryonic origin) was significantly higher than in
the other cell lines
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model of CD105+ RCC-CSCs derived from established
renal cancer cell lines. We showed that selected cell lines
comprised a variable number of CD105+ cells—referred
as to CD105high or CD105low cell lines—and that this
characteristic was independent of the cell culture source
in terms of RCC grade or stage, including primary- and
metastatic tumor derived cell lines. Surprisingly, primary
pRCC tumor cells (HKCSCs) isolated and cultured in
stem cell media were not enriched in CD105+ cells. A
significant subpopulation of CD105+ cells (>8% total
culture) was detected in the ASE cell line derived from a
prenatal kidney. This suggests that normal kidney stem
Fig. 5 Colony- and sphere-forming abilities of pRCC cell lines. a Representative images of colonies formed in semi-soft agar at different time points of
culture. From four tested cell lines, only two (ACHN and HKCSC) were able to generate colonies in semi-soft agar. The differences in colony morphologies
were noticed: ACHN created round-shaped colonies and HKCSC irregular-shaped. A quantitative analysis of viable colonies was done using the alamarBlue®
assay: HKCSCs created significantly more colonies than ACHN. b Representative images of cells grown in sphere-promoting conditions on the fifth day of
culture. ACHN were able to create aggregate-like structures. Caki-2 spheres were smaller and more round-shaped. The other cell lines, HKCSC and ASE, did
not form spheres in these conditions. A quantitative analysis of Caki-2 and ACHN spheres number showed no significant differences, although the ACHN
spheres were significantly bigger than the Caki-2 spheres
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cells may also be CD105+, especially as stemness-linked
TFs were expressed in those cells, which could confirm
the characteristics of a kidney side population (SP) as
previously reported [43].
We have shown that established pRCC cell line-
s—Caki-2 and ACHN—differed both in the number of
CD105+ cells and the stem-like phenotype expression.
The CD105low ACHN cell line expressed abundant oct-
4 TF but showed an increased ability for stem-like
behavior in comparison to the CD105high Caki-2 cell
line, including 3D growth in sphere-promoting condi-
tions and clonogenicity. This is in accordance with
research on melanoma cell lines, where no correlation
between CD105 expression and in vitro invasiveness was
observed [44]. Even though SP and CD105+ cells are
considered as stem-like cells in RCC, the ACHN cell line
must be considered in general to harbor a high stemness
phenotype. High stemness of ACHN was previously de-
scribed as high self-renewal capacity measured by the
ability to grow as spheres when cultured under serum-
free, attachment-free stem cell culture conditions [45].
Moreover, it has been previously shown that there is no
significant difference in the cell proliferative ability and
clonogenicity between the SP and other cells in the
ACHN cell line as both populations were highly aggres-
sive. Nevertheless SP cells in ACHN had a significantly
higher sphere forming ability than non-SP cells [17], and
CSCs were also isolated from the ACHN cell line based
on high ALDH expression [46, 47]. Therefore, it could
be concluded that CD105+, ALDH-high and SP cells
found in the ACHN cell line represent CSCs. However,
the ACHN cell line is, in general, highly aggressive and
Fig. 6 Hanging drop assay of pRCC cell lines. Representative images of aggregates formed by tested cell lines in a hanging drop assay. The HKCSC cell
line generated a homogeneous, compact 3D aggregate, while Caki-2, ACHN, and ASE remained loose and were bigger than the structure of HKCSC
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is challenging the CSCs research model because of en-
dogenous mesenchymal phenotype [48] with a higher
expression of N-cadherin and vimentin [49].
CD105, a component of the TGFβ receptor com-
plex, is a glycoprotein most often expressed by endo-
thelial cells. It is associated with angiogenesis and
tumor neovascularization, and has been shown as an
independent marker of a favorable prognosis in RCC.
High expression of this protein negatively correlates
with the nuclear grade and tumor stage of ccRCC
[50]. Surprisingly, an inverse relation seems to
characterize pRCC as higher CD105 expression corre-
lated insignificantly with a poor prognosis. At the
same time, 39% of pRCCs were negative for CD105
Fig. 7 The influence of oxygen on pRCC cell growth. a Relative expression of hif1 and hif2 genes was measured in real-time PCR in relation to the PPIA
housekeeping gene. Overexpression of hif1 was identified in Caki-2 and ACHN at various oxygen partial pressure compared to the control line (ASE). In
hypoxia, hif1 expression was significantly downregulated in Caki-2 only. Relative expression of hif2 showed a different profile than hif1; hypoxia
significantly downregulated the gene expression in Caki-2 and ASE, although in ACHN, a strong upregulation was observed. In both cases, hif1
and hif2 were not detectable in HKCSC. b Growth curves of cells cultured in monolayer in normoxic and hypoxic incubators were determined
with alamarBlue® assay. The third day of culture was taken to statistical analysis because of the strategy for further experiments. In the observation of
overall growth trends, hypoxia promoted proliferation of Caki-2 and ASE cell lines, and inhibited the proliferation of ACHN in a parallel lack of
the influence on HKCSC. c The percentage of cells in different phases of the cell cycle was analyzed by flow cytometry with PI staining. The
analysis revealed a significant influence of hypoxia on the G2/M arrest of ACHN, which correlated with the proliferation inhibition. In the case
of Caki-2 cells, which proliferated more in low O2, an increase in the percentage of cells in G2 phase was observed. For the rest of the cell
lines, oxygen partial pressure had no effect on the cell cycle
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compared to 25% ccRCC. However, as shown by
Dubinski et al. [51], in ccRCC, CD105 overexpression
was prognostic of a poor outcome. Later, Saroufim et
al. [52] revealed that CD105 expression must be dis-
tinguished between endothelial or tumor cell expres-
sion and that it has either a negative or a positive
correlation with the prognosis, respectively. However,
this analysis was limited to ccRCC; no information on
tumoral CD105 expression in pRCC has been re-
ported until now. In general, pRCC studies are under-
represented as this type of renal cancer is less
frequently diagnosed. In our study, CD105 expression
in pRCC cell lines negatively correlated with invasive-
ness in vitro. However, the differences in stem-like
features observed in our studies may be correlated
more with the RCC stage (metastatic vs. primary)
than with an abundance of CD105+ cells in culture.
Although the usability of CD133 as a general CSCs
marker is controversial [53, 54], in kidney-focused re-
search, the CD133+ cell population has been identified as
resident human renal progenitor cells of an adult normal
kidney [40]. CD133+ cells isolated from primary tumors
(nephrectomy specimens) of RCC were shown to promote
tumor vascularization and neoangiogenesis in the nude
mice model [37]. In another trial, CD133+/CD24+/CTR2
+ cells were tumorigenic and indicated as RCC CSCs/
TICs [55], as well as CD44+/CD133+/CXCR4+ [49] and
CD44+/CD105+/CD133+/CD90+ cells [56]. In our study,
CD133 was expressed at low levels in established RCC cell
lines, which is in accordance with previous data [38, 57].
Fig. 8 The influence of oxygen on gene expression. a Relative expression of cd105, cd133, oct4, and sox2 was measured by real-time PCR and presented as
a fold change (hypoxia/normoxia). Both Caki-2 and ACHN cell lines had an increased expression of TF genes (oct4 and sox2) in hypoxia, similar to ASE. The
expression of membrane marker genes (cd105 and cd133) was downregulated in Caki-2 and ASE by low O2. The opposite phenomenon was obtained for
cd105 and ACHN: hypoxia induced overexpression. Intriguingly, in HKCSC, none of the genes were detectable. b The percentage of CD105+ and CD133+
cells in tested cell lines was measured by flow cytometry and presented as a fold change (hypoxia/normoxia). Results from real-time PCR were confirmed
for both proteins, and a reduced amount of the CD105+ and CD133+ populations in Caki-2 and ASE were observed in hypoxia. In contrast
to gene expression, the CD105+ population was reduced in ACHN hypoxic cells
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Fig. 9 (See legend on next page.)
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However, the protein was abundant in healthy kidney ASE
cells, which was probably due to their prenatal origin and
low differentiation state [58].
CSC (tumor initiating) subpopulations were previously
effectively isolated from established cell lines including
RCC, mostly with the side-population isolation approach
(Rho-negative, Hoehst-negative, ALDH-positive) [17, 59,
60]. In particular, the SP-cells subpopulation isolated
with Hoechst 33342 dye from ACHN and RENCA cells
were 2.6 and 18%, respectively [15]. SP was later isolated
from 769-P, 786-O, OS-RC-2, SN12C, and SKRC39 cell
lines [22, 61]. However, currently, there are no reports on
the presence of CD105+/CD133+ subpopulations in
pRCC cell lines. We have demonstrated the presence of
CD105+ cells in established RCC cell lines, including 786-
O, SMKT-R2, SMKT-R3, 769-P, Caki-1, Caki-2, ACHN,
and RCC6 [62, 63]. In this study, we have shown that the
level of CD105+ cells in pRCC is not correlated to the
stem phenotype of cells, which may question the useful-
ness of the single surface marker (CD105) isolation ap-
proach to identify CSCs subpopulation in RCC in vitro
cell culture model.
The next aim of the study was to unravel the role of
hypoxia in pRCC invasiveness and the promotion of
stem-like features and marker expression. It is well de-
scribed that low O2 tension develops in tumors in vivo
[64, 65] and promotes a CSC phenotype [66]. Our study
revealed that selected pRCC cell lines exposed to hyp-
oxia in vitro increased the expression of stem-related
TFs (oct-4 and sox2). TF expression was observed both
in ACHN cells where growth was suppressed by low O2,
and in Caki-2 that proliferate more extensively in hyp-
oxia. The above mentioned TFs are known to be up-
regulated by HIF2 [67]; however, in tested cells, only
ACHN (but not the Caki-2 line) increased hif2 expres-
sion simultaneously with stem-related TFs in hypoxia.
This is in accordance with pRCC showing lower hif2 ex-
pression than ccRCC [68]. As a result, HIF2 (and HIF1)
may be of secondary importance in CSCs induction in
pRCC and other signaling pathways may be responsible
for Sox and Oct induction, in particular WNT and Cdx1
[56, 69, 70]. Nevertheless, the up-regulation of stem cell
TFs by hypoxia was not correlated with a stem-like
phenotype: clonogenicity, and high aggregation proper-
ties as expected [71]. Cancer cell migration potential
suggests the ability of cells to metastasize111. Cancer cell
movement in the wound healing assay corresponds to
the cell’s ability to exit a primary tumor, to penetrate
into blood vessels, and to finally spread in vivo. In many
cancer types, it has been proven that internal tumor
hypoxia induces cancer migration potential both in vivo
[72] and in vitro [73, 74], although our results show the
opposite. Regardless of the CD105 or CD133 level, all
analyzed cancer cell lines showed reduced migration po-
tential in hypoxia. This phenomenon may be the result
of an alternative hypoxia-response mechanism in ana-
lyzed pRCC cell lines compared to previous studies. An-
other pivotal reason is the inability to separately
measure two mechanisms—migration and proliferatio-
n—in a wound healing assay. In the ACHN cell line of
high stemness, we have shown a reduced rate of prolifer-
ation under hypoxia with G2/M arrest. However, a stem-
like phenotype of these cells was not upregulated by low
O2. On the other hand, Caki-2 cells, which proliferate
more rapidly in hypoxia, simultaneously exerted more
stem-like features and grew in large spheres, but not in
semi-soft agar while remaining in aggregates in a hang-
ing drop culture. Cumulatively, in vitro assays performed
to test cell line aggressiveness and tumorigenicity [75]
suggest that CD105high Caki-2 cells express a less ag-
gressive phenotype, but survive better in hypoxia. More-
over, CD105 expression is usually up-regulated by low
O2 tension, promotes vascularization, and protects cells
from hypoxia-induced apoptosis [76]. However, in our
study, CD105high cells (Caki-2) proliferated faster in
hypoxic conditions while CD105 expression was reduced
by hypoxia. The different reactions of Caki-2 and ACHN
cells to hypoxia was not dependent on p53 [77] nor on
vhl status [78], as both cell lines were the tp53/vhl wild-
type.
Conclusions
We did not observe a positive correlation of CD105
level and colony formation and clonogenicity in
tested ACHN and Caki-2 cell lines, neither in nor-
moxic nor hypoxic conditions. The Caki-2 pRCC cell
line, characterized as CD105high, had weaker stem
features when compared to the CD105low ACHN
cell line with a more aggressive phenotype. The dif-
ferences in stem potential of those cells describe the
(See figure on previous page.)
Fig. 9 The influence of oxygen on colony- and sphere-forming abilities. a Representative images of colonies were formed in semi-soft agar in normoxic
and hypoxic cultures. The number of viable ACHN colonies in normoxia was significantly bigger than in hypoxia, while there were no differences in
HKCSC. b Representative images of cells grown in sphere-promoting conditions at the fifth day of culture in normoxia and hypoxia. The ACHN cell line
showed reduced colonies and spheres in hypoxia, which is a reflection of similar hypoxic inhibition in monolayer culture. Caki-2 was not able to create
colonies; nevertheless, its number of spheres was greater in hypoxia, as was hypoxia-promoted Caki-2 monolayer proliferation. Alternatively,
HKCSC created colonies but not spheres
Matak et al. BMC Cancer  (2017) 17:21 Page 13 of 17
Fig. 10 Wound healing assay. a ACHN and HKCSC cell lines relatively covered scratched in hypoxia significantly less than in normoxia; hypoxia
inhibited the cell migration potential of those cells. However, in Caki-2 and ASE migration, potential differences in terms of oxygen were not
significant. b Representative images of migrating ACHN and HKCSC in normoxic and hypoxic conditions at 0 h and 24 h
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characteristics of primary and metastatic cells rather
than the contribution of CD105+. Also, in contrast
to other studies, we have shown that in the case of
pRCC, hypoxic conditions in vitro diminish the
stem-like properties of cell lines [79–85].
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